Calidi Biotherapeutics, Inc.
CLDI
$1.73
$0.1710.90%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.62% | -21.70% | 18.94% | 12.36% | 20.18% |
| Total Depreciation and Amortization | 3.30% | 0.25% | 0.77% | 3.17% | 1.07% |
| Total Amortization of Deferred Charges | -- | -- | -55.56% | -43.75% | 0.00% |
| Total Other Non-Cash Items | -0.20% | -5.88% | 77.44% | -54.73% | -39.65% |
| Change in Net Operating Assets | 97.79% | -34.89% | -282.65% | 24.32% | -140.53% |
| Cash from Operations | 31.57% | -31.50% | -9.64% | 9.97% | -43.41% |
| Capital Expenditure | -714.29% | -40.00% | 16.67% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -714.29% | -40.00% | 16.67% | -- | 100.00% |
| Total Debt Issued | -- | -- | -100.00% | -- | -100.00% |
| Total Debt Repaid | 76.48% | -8,673.68% | -5.56% | 99.01% | -7,821.74% |
| Issuance of Common Stock | -99.97% | -26.06% | 264.85% | -32.19% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 73.42% | 40.04% | -129.03% | 14.20% | 1,023.17% |
| Cash from Financing | -105.78% | -38.14% | 116.77% | 16.27% | 72.59% |
| Foreign Exchange rate Adjustments | -- | -- | 148.48% | -153.85% | -176.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -656.70% | -87.39% | 625.16% | 445.60% | 61.91% |